Traws Pharma Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
TRAW$0.24+8.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| | | | | | | | |
|---|---|---|---|---|---|---|---|
| · · September 30, · · December 31, · | |||||||
| · · 2024 · · 2023 · | |||||||
| Assets · · · · · · | |||||||
| Current assets: | | | | | | | |
| Cash and cash equivalents | | $5,410,000 | | $20,821,000 | | ||
| Tax incentive and other receivables | | 2,121,000 | | 18,000 | | ||
| Prepaid expenses and other current assets | | 1,392,000 | | 1,821,000 | | ||
| Total current assets | | 8,923,000 | | 22,660,000 | | ||
| Property and equipment, net | | 12,000 | | 22,000 | | ||
| Other non-current assets | | 1,000 | | 1,000 | | ||
| Total assets | | $8,936,000 | | $22,683,000 | | ||
| Liabilities and stockholders’ (deficit) equity | | | | | | | |
| Current liabilities: | | | | | | | |
| Accounts payable | | $5,472,000 | | $5,619,000 | | ||
| Accrued expenses and other current liabilities | | 2,650,000 | | 3,375,000 | | ||
| Deferred revenue | | 226,000 | | 226,000 | | ||
| Total current liabilities | | 8,348,000 | | 9,220,000 | | ||
| Deferred revenue, non-current | | 2,621,000 | | 2,791,000 | | ||
| Total liabilities | | 10,969,000 | | | 12,011,000 | | |
| | | | | | | | |
| Commitments and contingencies | | | | | | | |
| | | | | | | | |
| Stockholders’ (deficit) equity: | | | | | | | |
| Series C Preferred stock, $0.01 par value, 5,000,000 shares authorized, 7,440 shares issued and outstanding at September 30, 2024 and no shares issued and outstanding at December 31, 2023 | | — | | — | | ||
| Common stock, $0.01 par value, 250,000,000 shares authorized, 3,025,554 and 840,251 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | | 30,000 | | 9,000 | | ||
| Additional paid in capital | | 617,202,000 | | 493,317,000 | | ||
| Accumulated deficit | | (619,232,000) | | (482,631,000) | | ||
| Accumulated other comprehensive loss | | (33,000) | | (23,000) | | ||
| Total stockholders’ (deficit) equity | | (2,033,000) | | 10,672,000 | | ||
| Total liabilities and stockholders’ (deficit) equity | | $8,936,000 | | $22,683,000 | | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.